A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease
Mary et al Sano
Bok Engelsk 1997
| Utgitt | 1997
|
|---|---|
| Omfang | 7 s.
|
| Utgave | Kopi
|
| Opplysninger | ABSTRACT. - BACKGROUND: There is evidence that medications or vitamins that increase the levels of brain catecholamines and protact against oxidative damage may reduce the neuronal damage and slow the progression of Alzheimer's disease.. - CONCLUSIONS: In patients with moderately severe impairment from Alzheimer's disease, treatment selegeline or alpha-tocopherol slows the progression of disease.. - METHODS: We conducted a doubleblind, placebo-controlled, randomized, multicenter trial in patients with Alzheimer's disease of moderate severity. A total of 341 patients received the selective monoamine oxidate inhibitorselegeline (10 mg a day), alphatocopherol(vitamin-E,2000 IU a day ), both selegeline and alpha-tocopherol, or placebo for two years.The primary outcome was the time to the occurrence of any of the following: death, institutionalization, loss of the ability to perform basic activities of daily living, or severe dementia (defined as a Clinical Dementia Rating of 3).. - RESULTS: Despite random assignment, the baseline score on the Mini-Mnetal State Examination was higher in the placebo group thanm in the other three groups, and this variable was highly predeictive of the primary outcome (P<0.001). In the unadjusted analyses, there was no statistically significant difference in the outcomes among the four groups. In analyses that included the base-line score on the Mini-Mental-State Examination as a covariate, there were significant delays in the time to the primary outcome for the patients treated with selegeline (median time,655 days;P=0.012), alpha-tocopherol(670 days, p=0.001) orcombination therapy(585 days, P=0.049), as compare with the placebo group (440 days).
|
| Emner |
